Laddar populära aktier...
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
142,701 Orion Corporation A shares converted into B shares
Orion Research Foundation grants EUR 1,109,000 for research in 2025
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
Orion Corporation: Managers’ transactions – Henrik Stenqvist
Orion Group Interim Report January–September 2024
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
Orion’s near-term climate targets approved by the Science Based Targets initiative
Orion’s collaboration partner Bayer submits application to U.
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
213,285 Orion Corporation A shares converted into B shares
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placeb...
Inside information: Orion upgrades full-year outlook for 2024
Orion Corporation: Managers’ transactions – Satu Ahomäki
Orion Corporation: Managers’ transactions – Niclas Lindstedt
Orion Corporation: Managers’ transactions – Liisa Hurme
Orion Corporation: Managers’ transactions – Hao Pan
44,767 Orion Corporation A shares converted into B shares
Orion Group Half-Year Financial Report January–June 2024
Orion Corporation’s financial reporting and Annual General Meeting in 2025
Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-...
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigationa...
Orion is developing the Finnish life science industry in a unique collaboration project
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025
Orion Corporation: Managers’ transactions – Eija Ronkainen
Orion Corporation: Managers’ transactions – Ari Lehtoranta
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
Orion Corporation: Managers’ transactions – Karen Lykke Sørensen
Orion Corporation: Managers’ transactions – Kari Jussi Aho
Orion Corporation: Managers’ transactions – Maziar Mike Doustdar
Orion Corporation: Managers’ transactions – Hilpi Rautelin
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.
Composition of the Nomination Committee of Orion Corporation
Orion Group Interim Report January–March 2024
Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024
Change in Orion Group Executive Management Board: change in Orion's group-level functions
The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing...
Orion Corporation: Organising meeting of the Board of Directors
Decisions taken by Orion Corporation’s Annual General Meeting on 20 March 2024
Orion Corporation: Managers’ transactions – Jari Karlson
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
Orion Corporation: Managers’ transactions – Virve Laitinen
Orion Corporation: Managers’ transactions – Olli Huotari
Orion Corporation: Managers’ transactions – Outi Vaarala
Orion Corporation: Transfer of 150,118 own B shares on 1 March 2024
Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published
Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally
Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland
Notice to the Annual General Meeting of Orion Corporation
Orion Group Financial Statement Release January–December 2023
119,021 Orion Corporation A shares converted into B shares
Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024
Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR...
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant P...
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
87 000 Orion Corporation A shares converted into B shares
Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution)
Orion Corporation: Managers’ transactions – Mikael Silvennoinen
Orion Corporation: Managers’ transactions – Agendum Oy
Orion Research Foundation grants EUR 1,112,000 for research in 2024
Orion Group Interim Report January–September 2023
Orion publishes Interim Report for January–September 2023 on Thursday 26 October 2023
Change in Orion Group's Half-Year Financial Report 2024 publication date
24 000 Orion Corporation A shares converted into B shares
Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture
European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency dis...
Orion Group Half-Year Financial Report 1–6/2023
Orion Corporation's financial reporting and Annual General Meeting in 2024
Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024
Orion publishes Half-Year Financial Report for January–June 2023 on Monday 17 July 2023
Orion invests EUR 30 million to increase production capacity in Finland
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Keskinäinen Eläkevakuutusyhtiö Ilmarinen)
570 000 Orion Corporation A shares converted into B shares
CORRECTION: Orion Corporation: Managers’ transactions – EVK-Capital Oy
Orion hosts its Capital Markets Day today, May 25, 2023, in Helsinki
